Printer Friendly

ADVANCED TISSUE SCIENCES FILES TO EXPAND DERMAGRAFT(TM) CLINICAL TRIALS TO DIABETIC AND DECUBITUS ULCERS

 ADVANCED TISSUE SCIENCES FILES TO EXPAND DERMAGRAFT(TM)
 CLINICAL TRIALS TO DIABETIC AND DECUBITUS ULCERS
 LA JOLLA, Calif., July 31 /PRNewswire/ -- Advanced Tissue Sciences Inc. (NASDAQ-NMS: ATIS) today announced that it has filed two additional supplements to its Investigational Device Exemption (IDE) with the Food and Drug Administration (FDA). The supplements seek to expand clinical trials of the company's living human skin replacement, Dermagraft(TM), to patients with diabetic and decubitus ulcers, according to Bernard D. King, M.D., senior vice president, Research and Clinical Development.
 "Decubitus and diabetic ulcers respond poorly to currently available treatments and can persist for months or even years," said King. "We believe that Dermagraft, with its dense dermal matrix, will provide the healthy dermal tissue necessary to support epidermal cell migration and wound closure."
 Diabetic and decubitus ulcers affect approximately 2.5 million individuals in the United States each year. If approved by the FDA, Dermagraft could be used to treat an estimated one-half to three- quarters of a million of these ulcer patients. Dermagraft is already in clinical trials under an IDE for the treatment of severe burns and chronic venous skin ulcers.
 Advanced Tissue Sciences is a tissue engineering company engaged in the growth of human tissues and organs for potential therapeutic and laboratory applications. Using its proprietary three-dimensional culture system, the company has successfully replicated a variety of human tissues including skin, cartilage, oral mucosa, bone marrow and liver.
 -0- 7/31/92
 /CONTACT: James P. Linton, Ph.D., of Advanced Tissue Sciences, 619-450-5707/
 (ATIS) CO: Advanced Tissue Sciences Inc. ST: California IN: MTC SU:


LS-KJ -- SD002 -- 5434 07/31/92 08:04 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 31, 1992
Words:273
Previous Article:HEALTH INSURANCE COMPANY REBATES MONEY
Next Article:J.D. POWER AND ASSOCIATES AWARDS 'BEST IN PRICE CLASS' VEHICLES
Topics:


Related Articles
ADVANCED TISSUE SCIENCES' DERMAGRAFT(TM) STUDIES PRESENTED AT BURN CONFERENCE
ADVANCED TISSUE SCIENCES RECEIVES APPROVAL TO EXPAND DERMAGRAFT(TM) CLINICAL TRIALS TO DECUBITUS AND DIABETIC ULCERS
ADVANCED TISSUE SCIENCES ANNOUNCES INTERIM ANALYSIS SHOWS DERMAGRAFT(TM) MEETING CLINICAL TRIAL OBJECTIVES IN DIABETIC FOOT ULCERS
Advanced Tissue Sciences - Dermagraft Clinical Performance
Advanced Tissue Sciences - Dermagraft(R) Clinical Update
Advanced Tissue Sciences Provides Dermagraft(R) Clinical Update
Advanced Tissue Sciences and Smith & Nephew Expand Dermagraft(R) Joint Venture
Advanced Tissue Sciences Raises $25 Million in Private Placement And Extends $50 Million Equity Line
Advanced Tissue Sciences Announces Second Quarter Results

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters